EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische Studie

Antifibrotics in rheumatoid arthritis-associated interstitial lung disease – real-world data from a nationwide cohort

Ana Catarina Duarte, Carlos Marques Gomes, Margarida Correia, Beatriz Mendes, Carolina Mazeda, Francisca Guimarães, Joana Abelha-Aleixo, Miguel Guerra, Roberto Pereira da Costa, Tiago Meirinhos, Maria José Santos

ARP Rheumatology · 2024

DOI: 10.63032/popm9413 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift ARP Rheumatology, 2024. Verfasst von Ana Catarina Duarte und 10 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Garcia de Orta, Unidade Local de Saúde Almada-Seixal. Hauptthemen laut MEDLINE: Lung Diseases, Interstitial, Arthritis, Rheumatoid, Pyridones, Indoles. Die Arbeit wurde bisher 11-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Interstitial lung disease (ILD) is the most common pulmonary manifestation of rheumatoid arthritis (RA) and is associated with an increased mortality. Clinical trials have shown that antifibrotics (nintedanib and pirfenidone) can slow the progression of connective tissue disease-associated ILD. This study aims to evaluate the effectiveness and tolerability of antifibrotics in a national, real-world cohort of patients with RA-ILD. Material and methods: We conducted an observational multicenter study of RA-ILD patients treated with antifi brotics, who were prospectively followed in Reuma.pt. Demographic and clinical data, pulmonary function tests (PFTs) results and adverse events (AEs) were collected. A linear mixed model with random intercept was used to compare PFT results within 12 (±6) months before to 12 (±6) months after antifibrotic initiation. Drug persistence was evaluated using Kaplan-Meier curves.

Results

We included 40 RA-ILD patients, 27 (67.5%) initially treated with nintedanib and 13 (32.5%) with pirfeni done. Most of the patients were female (55%), and current or past smokers (52.5%). At antifibrotic initiation, mean age was 70.9 ± 7.1 years and median ILD duration 5.0 [IQR 2.3-7.5] years. A total of 20 patients were included in effectiveness analysis, with the use of antifibrotics interrupting the decline of forced vital capacity (FVC; decline 300 ± 500 mL in the year before antifibrotic initiation vs. improvement of 200 ± 400 mL in the year following antifibrotic initiation, p=0.336) and total lung capacity (TLC; decline 800 ± 300 mL in the year before antifibrotic initiation vs. improvement of 600 ± 900 mL in the year following antifibrotic initiation, p=0.147). However, diffusion capacity for carbon monoxide remained in decline (3% decline in the year before antifibrotic initiation vs. 2.9% decline in the year following antifibrotic initiation, p=0.75). AEs were reported in 16 (40%) patients and led to drug discontinu ation in 12 (30%). Median duration of drug persistence was 150.3 weeks (95 %CI 11.0-289.6), with no difference between nintedanib and pirfenidone (p = 0.976).

Conclusion

This study with real-world data corroborates the usefulness of antifibrotics in stabilizing lung function, based on FVC and TLC. However, AEs were frequently reported and were the main cause for drug discontinuation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung Diseases, InterstitialArthritis, RheumatoidPyridonesIndolesAntifibrotic AgentsHumansFemaleMaleMiddle AgedAgedRespiratory Function TestsCohort StudiesTreatment OutcomeProspective Studies

Substanzen

nintedanibPyridonespirfenidoneIndolesAntifibrotic Agents

Autor:innen und Institutionen

  • Hospital Garcia de Orta, Unidade Local de Saúde Almada-Seixal.
  • Centro Hospitalar Universitário de São João, Unidade Local de Saúde de São João.
  • Hospital de Braga, Unidade Local de Saúde de Braga.
  • Hospitais da Universidade de Coimbra, Unidade Local de Saúde de Coimbra.
  • Hospital Infante D. Pedro, Unidade Local de Saúde da Região de Aveiro.
  • Unidade Local de Saúde do Alto Minho.

Zitieren

APA

Duarte, A. C., Marques Gomes, C., Correia, M., Mendes, B., Mazeda, C., Guimarães, F., Abelha-Aleixo, J., Guerra, M., Pereira da Costa, R., Meirinhos, T., & Santos, M. J. (2024). Antifibrotics in rheumatoid arthritis-associated interstitial lung disease – real-world data from a nationwide cohort. ARP Rheumatology. https://doi.org/10.63032/popm9413

Vancouver

Duarte AC, Marques Gomes C, Correia M, Mendes B, Mazeda C, Guimarães F, et al. Antifibrotics in rheumatoid arthritis-associated interstitial lung disease – real-world data from a nationwide cohort. ARP Rheumatology. 2024. doi:10.63032/popm9413

BibTeX
@article{Duarte2024,
  author = {Duarte, Ana Catarina and Marques Gomes, Carlos and Correia, Margarida and Mendes, Beatriz and Mazeda, Carolina and Guimarães, Francisca and Abelha-Aleixo, Joana and Guerra, Miguel and Pereira da Costa, Roberto and Meirinhos, Tiago and Santos, Maria José},
  title = {Antifibrotics in rheumatoid arthritis-associated interstitial lung disease – real-world data from a nationwide cohort},
  journal = {ARP Rheumatology},
  year = {2024},
  doi = {10.63032/popm9413}
}
Kostenlos starten →